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Abstract
Background: Medical progress and the lifestyle modification have prolonged life expectancy, despite the development
of chronic diseases. Support and care for older subjects are often provided by a network of informal caregivers composed
of family, friends and neighbors, who are essential in helping older persons to continue living at home. It has been shown
that the extent and diversity of informal tasks may jeopardize the physical, mental and social wellbeing of caregivers.
Methods/design: The aim of the Informal Carers of Elderly cohort is to define, through a longitudinal study,
profiles of caregivers of older patients with a diagnosis of one of the following diseases: cancer (breast, prostate,
colorectal), neurodegenerative diseases (Parkinson’s disease, Alzheimer’s disease and similar diseases), neurovascular diseases
(stroke), sensory diseases (age-related macular degeneration (AMD)) and heart disease (heart failure). Patients must be at
least 60 years old and living in the region of Burgundy-Franche-Comte (France). By following the different phases of the
caregiving relationship from the announcement of the diagnosis, it will be possible to assess the quality of life of caregivers,
coping strategies, levels of anxiety and depression, social support and the extent of their burden. We will also evaluate the
efficacy and efficiency of the implementation of a pragmatic intervention by a social worker to help informal caregivers,
through a randomized interventional trial nested in the cohort. Qualitative approaches aimed at studying the caregiver/
patient relationship, and situations leading to breakdown of the caregiver relationship will be also undertaken.
Discussion: Through an analytical and longitudinal definition of profiles of informal caregivers, this study will gather
detailed information on their life courses and their health trajectory by identifying consequences associated with the
concept of their role as carers. In addition, the randomized interventional trial will explore the relevance of the
implementation of a supportive intervention by a social worker to help caregivers. These data will help to identify
strategies that could be used to improve the existing sources of aid and to propose new approaches to help
caregivers. This study will provide the opportunity to identify the most relevant means of support adapted to
caregivers, and provide an impulse for new health care policies.
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Background
In France, almost four million people provide informal
care on a daily basis to people aged 60 years and over
[1]. The topic of informal caregiving has become a key
issue with regard to care and support for, and consequently
maintenance at home of, chronically ill older people, and
the features and progress of their dependence. Caregivers
play an essential role in providing support to patients [1–4].
Different reasons lead people to become caregivers of a
patient, such as chronic disease (51 %), older age (44 %),
physical handicap (30 %) and mental handicap (13 %) [2].
Among the various diseases, Alzheimer’s disease is the
most frequent cause of becoming an informal caregiver
(17 %), followed by age-related macular degeneration
(AMD) (15 %), heart failure (14 %), hypertension (13 %),
cancer (12 %), stroke (10 %), diabetes (9 %), osteoporosis
(8 %) and Parkinson’s disease (4 %) [2]. Over the last few
years, informal caregivers have been classified as a frail
population with an increased risk of health problems them-
selves. Psychological components of the informal caregiver
role, especially chronic stress, are associated with an in-
creased risk of depression, mortality and cardiovascular or
neurovascular morbidity [5–7]. The mean duration of infor-
mal caregiving situations is about 7 years, and the delivering
of care often has deleterious effects on the caregiver’s gen-
eral health. Forty percent of caregivers believe themselves
to be in poor health, although 90 % of caregivers say that
they can cope with the difficulties arising from the care
relationship. However, they report a deterioration of their
family life (35 %), marital life (41 %), mood (49 %), physical
condition (57 %) and leisure activities (70 %) [4].
The psychological distress felt by informal caregivers
seems to be directly related to the care provided: the
time devoted to care and support, the nature of the care,
and behavioral disorders. Such distress could be generated
by the effects of personal investment in the role of care-
giver, namely a reduction in personal leisure time, loss of
social links, family conflict and financial difficulties. The
care relationship leads to an increase in workload, which is
likely to accentuate any latent health problem of the care-
giver [8]. The “adjustment” must be made at the cost of
time devoted to family, friends or work. Accordingly, 29 %
of caregivers think that there is a lack of moral and emo-
tional support [2]. The difficulties experienced by caregivers
may, therefore, have a direct impact on the quality of the
care provided to patients [9]. It thus seems essential to
identify caregivers’ profiles through a longitudinal follow-up
of their life course, to study the course of their quality of
life, to understand the context in which care is provided, to
identify factors that amplify or attenuate “burn-out,” to
measure the impact of support on the caregiver’s life, to
understand strategies for coping with the stress, and to
identify psychological issues. Another important issue is the
identification of the most appropriate type of support that
could prevent the deterioration of the caregivers’ physical
and mental health, and preserve their social environment,
thereby ensuring the continuity of therapeutic care to
patients. Various forms of support for caregivers are
currently available. Previous studies have underlined
the efficacy of these interventions for both caregivers
and patients [10]. The effects varied according to the
age and gender of the caregiver, the social link between
caregivers and patients, the duration, the frequency of
the “work/care” and the type of intervention. The pa-
tient’s disease is also a key component.
To date, few longitudinal studies of caregivers have been
conducted. As a result, there is a lack of data to identify
caregivers’ profiles in a dynamic construct perspective.
Thus, there is a clear need for scientifically validated know-
ledge of this population. This is a key step in identifying
interventional strategies that could be applied and tailored
to the caregivers’ profiles. Our hypothesis is that caregivers
represent a heterogeneous group of individuals with differ-
ent needs and different coping strategies. As suggested by
previous reports, the support proposed to informal care-
givers should be varied and adapted to the individual. In
this respect, the Eurofamcare study underlined the need for
a systematic evaluation of the role and needs of caregivers
[11]. In addition, a meta-analysis showed the importance of
screening for burn-out in caregivers on a 6-monthly basis
[12]. Other studies have shown how the circumstances in
which a person comes to take on the role of caregiver can
affect the caregiver-patient relationship. Indeed, in the long
term, the relationship devoted to care may be compro-
mised. In this regard, proactive interventions initiated from
the earliest stages of the caregiving relationship seem essen-
tial in promoting optimized coping [13–18].
These points led us to undertake a longitudinal cohort
study to follow the informal main caregivers of patients
who are in the early phase of a diagnosis of breast, pros-
tate or colorectal cancer, Alzheimer’s or similar diseases,
Parkinson’s disease, stroke, AMD or heart failure.
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Methods/design
Trial design
This research project is a prospective, multicenter, longi-
tudinal cohort study incorporating two types of study,
namely an observational study and a nested randomized
interventional trial among caregivers included in the
observational study.
Observational study
The primary objective of the observational study is to
evaluate, using quantitative approaches, the patterns of
informal caregivers for patients aged 60 years and older
according to the evaluation of their health-related quality
of life (HRQoL) (as assessed by the Medical Outcome
Study Short Form-36 items (MOS SF-36) and the Care-
Giver Oncology Quality of Life (CarGOQoL) question-
naires (only for caregivers of the group of cancer patients),
coping strategies (as assessed by the coping scale developed
by Borteyrou, Truchot and Rascle [35]), anxiety and de-
pression (as assessed by the Hospital Anxiety and Depres-
sion Scale (HADS)), social support (as assessed by the
Social Support Questionnaire (SSQ6)) and caregiver bur-
den (as assessed by the Zarit Caregiver Burden Interview)
during the first 5 years of their role as caregivers.
Using qualitative approaches, the secondary objectives
are: (1) to evaluate the caregiver/patient relationship and
changes in this relationship over time as the patient’s
disease progresses, (2) to describe the specificities of the
attachment relationship between a caregiver and a patient
with behavioral disorders (Alzheimer-type dementia in par-
ticular) and (3) to study the situations leading to a break-
down in the role of caregiver (nursing home placement,
death or disease remission) during the 5 years of participa-
tion in the cohort duration.
Interventional study
A randomized interventional trial in a 1:1 ratio will be
conducted within this cohort to evaluate the effect of a
pragmatic supportive intervention on caregivers, pro-
vided by a social worker and an information booklet
(intervention arm) versus the control arm, where care-
givers will only receive the information booklet, without
social worker support. The intervention will be conducted
during the first 2 years of entrance into the caregiver’s role.
The intervention proposed here mobilizes social workers
of the Departmental Councils, of the General National
Retirement Fund (CARSAT Burgundy-Franche-Comté)
and of the Community Social Action Association (CCAS
of Dijon). All institutions providing social workers are offi-
cially involved in the study and all social workers are
trained in the management of older people, characteristics
of caregiving relationships and in ICE cohort study proce-
dures. The structure and purposes of the social worker’s
intervention are described in Table 1. The main objective
is to compare the mental and physical health summary
scores on the MOS SF-36 at 1 year between the two
groups. Secondary objectives are to compare the fol-
lowing parameters between groups: (1) the mental and
physical health summary scores of the MOS SF-36 at
2 years, (2) all HRQoL dimensions of the MOS SF-36
at 1 year and at 2 years, (3) longitudinally: all HRQoL
dimensions of the MOS SF-36 and the CarGOQoL
questionnaire (only for caregivers of the cancer patient
group), (4) coping strategies (as assessed by the coping
scale developed by Borteyrou, Truchot and Rascle [35]),
(5) anxiety-depression (as assessed by the HADS), (6)
social support (as assessed by the SSQ6) and the per-
ceived caregiver burden (as assessed by the Zarit Care-
giver Burden Interview) and (7) to assess from a societal
perspective the incremental cost-effectiveness ratio
(ICER) of the intervention of a social worker for care-
givers. The ICER will be expressed in terms of quality-
adjusted life years (QALYs) gained based on a utility score
that will be calculated based on the EuroQoL EQ-5D
Table 1 Content and purposes of the pragmatic intervention
by a social worker in the intervention group of the nested
randomized trial for caregivers
Format of the intervention:
For each caregiver randomized to the intervention arm of the trial, a
social worker will conduct an individual interview with the caregiver
Purposes of the interview:
To simply listen to the caregiver and allow them to express their complaints
(and to be attentive to unspoken complaints)
To evaluate the level of difficulty experienced by the caregiver in their
daily routine, being attentive to their personal situation
To respect and respond to any needs and/or requests expressed by the
caregiver, and provide active support; guarantee confidentiality of the
conversations and ensure that the caregiver participates willingly,
without intruding in their life
To provide any resources that are lacking in the caregiver-patient
relationship; provide information about available solutions for respite
care, and other solutions specific to each case (accommodation, health
care pathway, logistic/material support for the caregiver/patient)
To help the caregiver to more quickly apprehend and come to terms
with their commitment of being a caregiver
To be attentive to any alert signals and prevent deterioration towards
crisis situations (burn-out, abuse); to alert third parties if the caregiver is
found to be in a critical situation
Through their interactions with the caregiver, the social worker will
provide accompaniment and support, offering pertinent information
and orientation towards appropriate structures of care depending on
the situation the caregiver describes. The intervention leaves it to the
discretion of the social worker to decide what is the most appropriate
way to operate and the most appropriate solution to propose in
practice for each caregiver
The intervention also aims to determine whether the needs expressed
by the caregivers vary according to the patient’s disease, or according
to the patient’s age, sex or place of residence.
After the intervention, the social worker will complete a standardized Data
Transmission Sheet, with the Linear Analogue Scale Assessment quality of
life (LASA) questionnaire (about the caregiver but completed by the social
worker), to be forwarded to the study coordinator. They will receive receipt
of their submission once the forms have been submitted
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questionnaire, the SF-6D which is composed of 11 items of
the SF-36 questionnaire and the Center for Epidemiologic
Studies-Depression Scale (CES-D) questionnaires and eco-
nomic survey.
The duration of patients’ and caregivers’ participation in
the cohort study is 5 years. The entire cohort study’s dur-
ation is 10 years: 5 years of inclusions and 5 years of follow-
up. Only the interventional study is restricted to 2 years.
The logistic support of the study will be carried out by
three clinical research assistants (CRAs) (one in each
center) who are involved in the ICE cohort project and
who have also participated in the reflection phase during
the writing of the study protocol. They will be in charge
of patient screening, questionnaire sending, data collection
and for following patients/caregivers.
Study population
Inclusion criteria
To be eligible, patients must meet the following inclusion
criteria: they must be able to identify a primary caregiver
via a specific questionnaire and must consent to complete
this (if patients are unable to identify their caregiver them-
selves due to their disease, a form for self-designation as
primary caregiver will be available); patients must be aged
60 years or older and residing in the region of Burgundy-
Franche-Comté; they must have recently been diagnosed in
hospital or in a private-sector medical practice with one or
more of the following diseases: local or metastatic cancer
diagnosed within the previous 6 months (breast cancer in
first-line chemotherapy treatment, hormone-sensitive pros-
tate cancer, colorectal cancer in first-line chemotherapy
treatment); neurodegenerative disease (Parkinson’s disease
diagnosed within the previous 5 years, Alzheimer’s or
similar diseases diagnosed within the previous 12 months),
AMD, (geographic atrophy or neovascular AMD, diag-
nosed within the previous 12 months, with an acuity range
of between 2 and 6/10, aged 65 years or older and able to
complete the Mini-Mental State Examination (MMSE)
test); heart disease (heart failure diagnosed within the pre-
vious 3 months); neurovascular disease (ischemic or
hemorrhagic stroke with clinical evidence of post-stroke
lesions more than 24 h old, diagnosed within the previous
6 months and with a Rankin score ≤ 2).
The eligibility criteria of principal caregivers are as fol-
lows: they must be members of the patient’s social environ-
ment (family, friend or neighbor); they must be identified
by the patient as the “primary caregiver” based on the des-
ignation questionnaire or they must have completed the
self-designation form as primary caregiver; they must be
aged 18 years or older; they must not be employees of a
health care organization; they must be residing in the re-
gion of Burgundy-Franche-Comté; and they must be able
to complete the study questionnaires.
Noninclusion criteria
Any patient who has been previously diagnosed with an-
other targeted disease and/or those living in a retirement
home will not be included. Principal caregivers who are
under guardianship, curatorship or under the protection
of justice will be excluded.
Inclusion procedure
Inclusion will be performed in two steps. First, patients
will be identified, during a clinical consultation in the
context of a diagnosis for one of the diseases being in-
vestigated, by clinicians involved in the ICE cohort
study who had participated in the reflection phase on
inclusion strategies for the different diseases, the proce-
dures to recruit caregivers and the logistic support to
set up. At the first consultation, which is a medical visit
planned at hospital within the scope of the patient’s
pathology, the clinician will indicate the presence or
not of a potential informal primary caregiver. They will
ask the patient to come to the next consultation with
their caregiver (the timetable is defined according to
the inclusion strategy, depending on the patient’s path-
ology). Then, at the second consultation, two possibil-
ities for the inclusion of informal caregivers exist,
namely patients are either accompanied by their care-
giver or they attend unaccompanied. If the patient
comes to the second consultation with their caregiver,
as requested, both the patient and their caregiver will
be informed of the study, complete the identification
questionnaire with the health care facility CRA involved
in the study, and receive the Consent Form. Alterna-
tively, if the patient does not attend the consultation
with his caregiver, then the caregivers will be contacted
by phone based on the information provided by the pa-
tient in the identification questionnaire. An appoint-
ment will be made with the caregivers to present the
study to them and to give them the relevant informa-
tion concerning the study (information sheet) and the
Consent Form. If patients are unable to identify their
primary caregiver by themselves due to their health
status, a self-designation form as primary caregiver will
be proposed to the person(s) accompanying the patient
(Figs. 1 and 2).
Randomization procedure
Once all the caregivers’ inclusion questionnaires have
been completed (during the month following inclusion)
and collected by the CRA, randomization will be per-
formed for each group of diseases using a minimisation
technique. Minimization will be stratified, regardless of
the disease group, according to center, age (80 years or
older versus below 80 years) and gender. Additional
specific stratification factors are:
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1. For cancers: cancer localization (breast, prostate,
colorectal), stage (nonmetastatic and resectable
versus advanced or metastatic)
2. For Alzheimer’s disease: stage of disease (very early
stage (MMSE score ≥ 26) versus mild (20 ≤MMSE
score < 26) versus moderate (10 ≤MMSE score < 20)
versus severe (MMSE score < 10))
3. For Parkinson’s disease: stage of severity of
Parkinson’s disease (stages I to V according to
the Hoehn and Yahr classification) [19]
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4. For heart failure: severity of disease (according to the
New York Heart Association (NYHA) classification)
5. For neurovascular diseases: Rankin Score:
(nondependent Rankin ≤ 2 or dependent Rankin > 2)
6. For AMD: form of AMD, namely geographic atrophy
versus neovascular disease
Caregivers randomized to the intervention arm will
receive an information booklet and will receive support
provided by a social worker scheduled every 6 months for
2 years (from 6 to 24 months after inclusion). The duration
of the support will be 1 h per visit and will be defined in
two parts: firstly, administration of the Linear Analogue
Scale Assessment quality of life (LASA) questionnaire, and
secondly, a standardized semidirective interview to assess
needs. The LASA questionnaire will serve as a support tool
for the intervention to detect any health problems and
optimize the responses provided by the social worker [20].
LASA includes four HRQoL dimensions, namely global
quality of life, mental wellbeing, physical wellbeing, and
level of fatigue and, using a Visual Analogue Scale (VAS)
ranging from 0 (worst HRQoL level imaginable) to 10 (best
HRQoL level), assesses the caregiver’s perception of their
own health status. The social worker will then conduct a
semidirective interview to evaluate the caregiver’s needs
and to detect any early signs of burn-out.
In the control arm, caregivers will only receive the in-
formation booklet. This booklet will inform caregivers
about existing structures and support programs. Never-
theless, caregivers randomized to the control arm retain
the possibility to solicit the social services participating
in the study on their own initiative, or other appropriate
services, for social support if needed.
Sample size calculation
Observational and interventional studies
The calculation of the number of caregivers required
was based on both the design and the primary objectives
of the intervention study, with noncompetitive recruit-
ment according to each group of diseases (randomization
performed 1:1 per group). We aim to demonstrate the effi-
ciency of the intervention in each of the five groups of dis-
eases. The hypothesis is that the intervention proposed
will improve the HRQoL of caregivers on at least one of
the two summary scores of the MOS SF-36 (i.e., physical
health and/or mental health).
The minimal clinically important difference (MCID),
which is the smallest change in an outcome that a
patient would identify as important, was fixed at 5
points [21].
The null hypothesis (H0) is that there will not be a dif-
ference of at least 5 points between the two arms in at
least one HRQoL summary score at 1 year; while the alter-
native hypothesis (H1) is that there will be a difference of
at least 5 points between the two arms in at least one
HRQoL summary score at 1 year.
With a bilateral alpha risk of 5 % and a statistical power
of 90 % to detect a difference of at least 5 points (standard
deviation (SD) = 25), and adjusted to take account of the
number of statistical tests and maintain an overall alpha
type one error rate of 5 % (Bonferroni adjustment):
 With two dimensions of HRQoL, α’ = α/2 = 0.05/
2 = 0.025
 With five groups of diseases, α” = α’/5 = 0.025/5 =
0.005 (cancer (breast, prostate, colorectal);
neurodegenerative disease (Alzheimer’s disease and
similar diseases); AMD; neurovascular (stroke);
cardiac (heart failure))
 At least 1684 caregivers should be randomized in
each disease group. However, we anticipate lower
recruitment in the heart failure group. Accordingly,
only 488 caregivers will be randomized (bilateral α
type I error of 0.005 and statistical power of 80 %)
to demonstrate a difference of at least 5 points
(SD = 15). Thus, it will be necessary to include and
to randomize 4 × 1684 = 6736 caregivers, plus 488
in the heart failure group, representing a total of
7224 caregivers. An interim analysis will be planned to
reject either H0 or H1 (Alpha Spending Function and
O’Brien-Fleming Boundaries) when half the caregivers
have been included with 1 year of follow-up in each of
the subgroups. To allow for 5 % of loss to follow-up, it
will be necessary to include and randomize an
additional 380 caregivers, resulting in an overall
total of 7604 caregivers (1750 caregivers for each




Caregivers and patients’ sociodemographic data (sex, date
of birth, place of residence, matrimonial status, study level,
professional status) and patients’ medical data (type of
disease, stage of disease, treatment) will be collected by
the CRA by interviews or from medical files and recorded
via CleanWeb Designer™ software version 164.3.0
(Telemedicine Technologies SA).
Administration of questionnaires
Caregivers will receive the questionnaires by post or by an
email inviting them to complete the questionnaires online
via CleanWeb Designer™ software. Each participating care-
giver will be free to choose their preferred method for
completing the questionnaires. All questionnaires are self-
administered. The CRA will carry out sending and receipt
of questionnaires. If filled questionnaires are not received
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4 weeks after sending, a follow-up call will be performed
by the CRA.
A schematic diagram of time schedule for the administra-
tion of the different questionnaires is presented in Fig. 3.
Health-related Quality of life
The primary endpoint of the study is HRQoL. This will
be evaluated using the Medical Outcomes Study (MOS)
Short Form (SF)-36, which is a self-administered question-
naire [22–28]. It comprises 36 items divided into eight
scales, namely: physical functioning (10 items), role limita-
tions due to physical health (four items), pain (two items),
general health perceptions (five items), energy/fatigue (four
items), social functioning (two items), role limitations due
to emotional problems (three items), mental health (five
items) and health change (one item). The average time
required for completion is 5 to 10 min. It is the most fre-
quently used generic instrument, and has been translated
and validated in the French language in a wide range of dis-
eases [29, 30]. One score is generated per dimension, and
normalized on a scale of 0 (worst HRQoL) to 100 (best
HRQoL). Physical and mental health summary scores are
also generated.
HRQoL will also be evaluated for caregivers of cancer
patients using the CareGoQoL questionnaire. This self-
administered questionnaire includes 29 items assessing 10
HRQoL dimensions, namely: psychological wellbeing, bur-
den, relationship with health care professionals, financial
and administrative management, coping, physical well-
being, self-esteem, leisure activities, social support and
private life. For each individual, scores for a dimension are
computed if at least half of its contributive items are
answered. The score of each dimension is obtained by
computing the mean of the item scores for that dimen-
sion. An index is computed as the mean of the dimension
scores. All dimension scores and the index are linearly
transformed and standardized on a scale of 0–100 (the
higher the score, the better the HRQoL). This instrument
has recently been validated in French [31].
Anxiety and depression
Anxiety and depression will be assessed using the self-
administered Hospital Anxiety and Depression Scale
Fig. 3 A schematic diagram of time schedule for enrollment, interventions, assessments and visits for participants
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(HADS) questionnaire. This includes 14 items distrib-
uted in two subscales, namely an anxiety and a depres-
sion subscale. Each item is measured on a 0 to 3 scale.
The HADS has been used in various medical contexts
(hospitalized and nonhospitalized patients as well as
apparently healthy persons). It has also been validated
in the French language [32–34].
Coping
The coping strategies used by caregivers for stress adap-
tation will be identified using the coping scale developed
by Borteyrou, Truchot and Rascle [35]. It includes 25
items to assess six dimensions: escape strategies (behav-
ioral avoidance strategies that allow caregivers to leave the
care context), psychological and behavioral disengagement
strategies (avoidance strategies to protect against sources
of stress), positive reinterpretation strategies (cognitive
strategies to distance oneself emotionally from problems
encountered), distraction activities or behavioral strategies
that aim to restore resources (protective strategies to leave
the care context during which caregivers play an active
role in entertaining or social activities), and consultations
with a psychologist and seeking social support (emotional
strategies that aim to verbalize problems, express negative
emotions, exteriorize feelings without any obvious desire
to find solutions to problems). The validity of this tool has
been tested in professional caregivers and noncaregivers
in oncology. This coping scale will identify the processes
by which caregivers confront the stresses linked to their
care relationship.
Social support
The six-item Short Form of the SSQ6, which is validated
in French, will be used to qualitatively and quantitatively
evaluate the caregivers’ social network [36, 37]. The
SSQ6 is administered in two steps. During the first step,
respondents indicate the name or the initials of people
providing each social support described. In this way, a
list of persons in the network is established. In the second
step, respondents indicate, for each person, their degree of
satisfaction with regard to the support received. It is pos-
sible to calculate a total score for availability N by adding
the number of persons available for each type of support.
A satisfaction score for the support provided by the net-
work is calculated by adding scores obtained, which vary
from 1 to 5 [38].
Caregiver burden
The Zarit Caregiver Burden Interview will be used to
evaluate the burden represented by caring for a patient
living at home [39]. It reveals the degree of exhaustion or
psychological fatigue of caregivers. It is composed of 22
items, scored 0 to 4, divided into three dimensions: the re-
lationship with the person being cared for, repercussions
on caregivers’ life and their own emotional state. Re-
sponses are distributed on a scale of 5 points. The over-
all score shows whether there is a slight, moderate or
heavy burden or no burden at all. In addition to evalu-
ating the material and emotional burden, this inventory
also contains a complementary questionnaire of 27
items, scored 0 to 4, centered on the evaluation of
problems with the behavior and autonomy of the cared
person, scored according to their frequency and the
caregivers’ emotional reactions. The score sheet has two
parts: one part “frequency” and one part “relationship.”
The Zarit Caregiver Burden Interview is a reliable tool
that has been validated in French for the assessment of
caregiver burden [37].
Efficiency
A cost-utility analysis will be performed to compare the
two arms of the interventional study (intervention of a
social worker for caregivers versus no intervention) in
terms of costs and quality-adjusted life years (QALYs).
The point of view adopted will be the societal perspec-
tive. The societal perspective consists in aggregating all
expenditure, regardless of its nature and source of funding
(social security, private health insurance, out-of-pocket ex-
penses) [40]. The choice of this perspective is justified by
the diversity of the expected consequences of the interven-
tion of a social worker. Only direct medical costs will be
taken into account. They will include drugs and hospitaliza-
tions, medical consultations, all biological tests, medical/
technical procedures, and medical transportation related to
the caregivers’ health state. Social security benefits received
by caregivers will also be taken into consideration, as well
as costs associated with caregiving time and out-of pocket
expenses. Productivity costs will not be estimated because
it is usually considered that they are included in the QALY
estimation. However, the impact of the informal caregiving
on the caregivers’ professional situation will be evaluated
using the economic survey. QALYs will be calculated based
on the use of utility score from the EQ-5D, a multiattribute
generic questionnaire composed of six attributes: mobility,
self-care, usual activity, pain/discomfort and anxiety/
depression. Each attribute has three levels, thus defin-
ing 243 possible health states [41, 42]. In a sensitivity
analysis, another questionnaire aimed at estimating
utility scores will be used, namely the SF-6D. It is com-
posed of 11 items of the SF-36 questionnaire [43, 44].
The Center for Epidemiologic Studies-Depression Scale
questionnaire (Center for Epidemiologic Studies-Depression
Scale questionnaire (CES-D) will also be used to assess the
overall health of caregivers. It is a self-report instrument,
composed of 20 items, and validated in French for
evaluating depression [45]. Questionnaires will be ad-
ministrated to caregivers every 3 months during the
first 2 years of follow-up.
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Qualitative studies
The qualitative studies will make it possible to answer
the secondary objectives of this research:
1. To study the caregiver-patient relationship, we will
conduct semistructured interviews with 50
caregiver-patient pairs (10 pairs in each pathology
group). Interviews will be recorded and transcribed
in their entirety. These interviews (between 1 and
1.5 h long) will be performed with caregivers and
patients separately at baseline and every 6 months
thereafter over 5 years. Analysis of the interviews
will include: thematic content analysis of each interview
(first level of analysis), cross-sectional analysis of the
content of the caregiver/patient story (second level),
cross-analysis of the narratives collected from each
group of caregivers and elements of the relevant
literature (third level). These analyses will
characterize the predetermination of caregiving,
explore the experience of helping, retracing its
path and analyzing the mutual perception of the
aid relationship and the difficulties encountered.
2. To describe the specificities of the relationship when
the caregiver has to face behavioral and psychological
problems in the patient (Alzheimer-type dementia in
particular), we will compare two groups of 25
caregivers. The first group will be caregivers of
patients with dementia, and the second group
caregivers of patients with cancer. This study is
based on semistructured interviews and auto-
administered questionnaires. We will meet each
person every 6 months during the first 5 years of
their role of caregivers to evaluate the following:
(a)The quality of the attachment relationship using
the Relationship Scales Questionnaire (RSQ) [46]
(b)Alexithymia, using the Toronto Alexithymia Scale
(TAS) [47]
(c)Negative and positive reactions to caregiving using
the Caregiver Reaction Assessment [48].
3. To measure the “dispossession” of the caregiver role
when the patient is in remission, enters an institution
or dies and the repercussions of this event, and to
evaluate the consequences for caregivers, we will
perform, every 6 month after the event and until the
end of the cohort, semidirective interviews with 90
caregivers whose patient had had a disease remission
(30 caregivers), entered an institution (30 caregivers)
or died (30 caregivers).
Analysis
Analyses will be performed using SAS (version 9.4) (SAS
Institute Inc., Cary, NC, USA), R (version 3.2.2) [49] and
Stata (v13) (StataCorp LP, TX, USA) software. The
statistical analysis plan for the primary and secondary
objectives will be written before the database is locked.
All analyses will be on a modified intention-to-treat
principle, i.e., including all randomized informal carers
regardless of the eligibility criteria and intervention re-
ceived, with MOS SF-36 scores available at baseline and
1 year. Analyses for the interventional study will be done
on an intention-to-treat basis. After Bonferroni adjust-
ment, statistical significance will be fixed at the 0.005
level for primary analyses, and at the 0.05 level for the
secondary objectives.
An interim analysis is planned when half of the pa-
tients will be included to reject or not H0 (efficacy) or
H1 (futility); the Alpha Spending Function with O’Brien-
Fleming Boundaries will be used to determine the alpha-
level significance at the interim and at the final analysis
using EAST® software (Cytel Software Corporation,
Cambridge, MA, USA) [50]. The corresponding confi-
dence interval will be computed (1 − alpha level).
Sociodemographic and clinical characteristics will be de-
scribed at inclusion using frequency (percent) for qualita-
tive variables and mean (SD), or median (min–max) for
continuous variables. Data will be compared between
randomization arms using the Student t test or the non-
parametric Mann-Whitney test, or analysis of variance
(ANOVA) or the Kruskal-Wallis test for continuous vari-
ables and the Chi-squared or Fisher’s exact tests for quali-
tative variables, as appropriate. Scores will be described at
each follow-up time point using mean (SD) and median
(min–max) in each arm.
After describing missing data and investigating the
mechanism of missing data profiles, imputation will be
performed using a multiple imputation method by sensi-
tivity analysis after checking normality, and univariate
and multivariate ANOVA adjusted for baseline score will
be performed to compare the two summary scores of
the SF-36 questionnaire at 1 and 2 years.
Multivariate analyses will be performed including at
least the stratification criteria for randomization, as well
as variables associated with HRQoL at the 10 % level by
univariate analysis. HRQoL data will also be longitudinally
analyzed using a mixed model of analysis of variance for
repeated measures (or pattern mixture models in case of a
missing-not-at-random profile) in order to test an arm ef-
fect, time effect and an interaction between arm and time,
as well as the effect of other relevant parameters (HADS,
coping, clinical parameters, etc.). Some random effects on
patients will also be introduced into the model in order to
reflect individual trends. Burden, coping and HADS will
also be modeled as time-dependent covariables in another
model. Time to HRQoL score deterioration will be esti-
mated using the definitions of both Bonnetain et al. [51]
and Hamidou et al [52]. Item Response Theory, cluster
analyses, structural equation modeling as well as classical
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factorial analyses will be conducted as complementary
analyses to define and validate longitudinal profiles of
caregivers. All these analyses will be repeated in each sub-
group defined by stratification (including cancer localiza-
tions) for sensitivity analyses.
Efficiency
Outcomes will be expressed as incremental cost-effectiveness
ratios (ICERs) (i.e., the difference in overall mean direct
medical costs divided by the difference in mean QALYs
between the two groups) and cost-effectiveness accept-
ability curves. The absence of intervention will be con-
sidered as the reference strategy. Costs and QALYs will
be discounted at a rate of 3 % per annum. The robustness
of results will be assessed through a one-way sensitivity
analysis based on the use of the SF-6D. A standard
nonparametric bootstrap simulation will also be con-
ducted (10,000 replications) to estimate the 95 % confi-
dence interval of the ICER.
In case of missing assessments concerning utility scores,
the last observation will be carried forward. Differences in
mean utility scores and mean costs between the interven-
tion and control groups will be assessed by the nonpaired
t test (for variables with a normal distribution) and the
nonparametric Mann-Whitney test (for variables with a
nonnormal distribution).
Discussion
The scientific purpose of the ICE cohort study is to define
longitudinal profiles of caregivers and to evaluate pragmatic
action to support them. This study should make it possible
to improve our knowledge concerning the life course of
caregivers (by identifying profiles of the caregivers and un-
derstanding the mechanisms involved in changing this pro-
file), to identify their needs and their expectations (in terms
of professional support, financial assistance, information
and advice to assist in caregiving) and to envisage optimized
support for patients with chronic disease who live at home.
The consideration of patients’ social environment is
essential in an integrative approach to the management
of their disease. In this respect, the difficulties encoun-
tered by caregivers may have direct implications on the
quality of the care they provide. This study will allow us
to identify factors associated with modifications in pa-
tient management support. Improved knowledge of the
difficulties that caregivers face in their everyday lives
could contribute to identifying potentially high-risk situ-
ations in the care relationship (e.g., mistreatment) and
make it possible to implement timely support for care-
givers at risk of psychological, physical or social distress.
The purpose, in terms of public health, is to avoid the
health deterioration of caregivers, and thus indirectly, to
improve the patient’s health status through optimized man-
agement that is potentially inexpensive and economically
acceptable for society. The intervention study is based on
the hypothesis that early intervention during the initial
phase of the care relationship is likely to improve the care-
givers’ HRQoL and the quality of the support provided.
The hypothesis of the associated efficacy study is that the
intervention of a social worker, through their role in
listening, alerting, advising and guiding, may improve
the wellbeing of informal caregivers, and thus reduce
their potential consumption of health care resources,
and consequently, the expenditure related to their care
mission. Improving caregivers’ HRQoL and preventing
degradation of their health will make it possible to posi-
tively influence the patients’ HRQoL, and as a result,
their health, autonomy and capacity to continue living
at home. To ensure the homogeneity of the intervention
across the Burgundy-Franche-Comté region, all registered
social workers in the region will undergo study-specific
training. The intervention to be provided in the context of
this study by social workers is explained in detail and for-
malized in a partnership agreement signed by all the social
services employing social workers in the region.
The ICE cohort may lead to the formulation of health
recommendations and serve as a basis for the development
of services that offer support to caregivers to reduce the
potential risk of social inequalities related to caregiving.
Trial status
At the time of manuscript submission, a feasibility study
conducted to test the inclusion mechanisms in the clin-
ical departments, as well as the questionnaire concern-
ing the designation of the principal caregiver, has been
completed. The feasibility study that was carried out
from 2013 to 2015 allowed us to test the acceptability of
the study and the questionnaires with the patients and
their caregivers, to better understand the logistic and op-
erational aspects. The project protocol has been modi-
fied to reflect the results of the feasibility study. Official
recruitment to the ICE cohort started in September
2015. The first patient was recruited on 2 October 2015.
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